Stocks · Healthcare · Biotechnology
Champions Oncology, Inc. CSBR
$4.94 +1.23% Close, Oct 2, 2026 · NASDAQ · Market cap $68.6M
Weak trend
Next earnings report: Dec 15, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.08, down 139.4% year over year.
- Net debt is 14.8× EBITDA, a high level of leverage.
- Operating margin narrowed to -1.7% from 5.3% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 45%
- EPS growth (TTM, YoY)Bottom 16%
- FCF growth (TTM, YoY)Bottom 6%
- Revenue growth, 3-year CAGRBottom 33%
- Revenue growth accelerationTop 26%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 39%
- Gross marginBottom 33%
- Operating marginTop 44%
- Accruals (lower is better)Bottom 6%
- Net debt / EBITDA (lower is better)Bottom 4%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 34%
- Free-cash-flow yieldBottom 39%
- EBITDA / enterprise valueTop 36%
- Sales / enterprise valueTop 14%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 23%
- 6-month returnBottom 27%
- 1-year return vs S&P 500Bottom 27%
- Distance from 52-week highBottom 40%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 41%
- Upside to consensus price targetTop 27%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 30%
- Maximum drawdown, 3 yearsTop 34%
- Beta vs S&P 500 (lower is better)Top 8%
- Net debt / EBITDA (lower is better)Bottom 4%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 4.4% | 6.7% | ↑ |
| EPS growth (YoY) | -124.6% | -139.4% | ↓ |
| Gross margin | 48.5% | 49.3% | ↑ |
| Operating margin | 5.3% | -1.7% | ↓ |
| FCF margin | 12.7% | -10.1% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 6.7% | 4.4% | ↑ | Bottom 45% |
| EPS growth (TTM, YoY) | -139.4% | -124.6% | ↓ | Bottom 16% |
| Gross margin | 49.3% | 48.5% | ↑ | Bottom 33% |
| Operating margin | -1.7% | 5.3% | ↓ | Top 44% |
| Net margin | -1.9% | 5.1% | ↓ | — |
| Free-cash-flow margin | -10.1% | 12.7% | ↓ | — |
| Return on invested capital | -6.8% | — | Top 39% | |
| Revenue growth, 3-year CAGR | 3.3% | — | Bottom 33% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 13.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 3.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +36.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 14.79×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.38%
- Shareholder yield
- -0.38%
- Share count change, 1 year
- +0.8%
- Share count change, 3-year CAGR
- +1.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jul 31, 2026 (filed Sep 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +7.0%
- Positive 20 days after report
- 2 of 7
Analysts
- Consensus price target
- $12.00
- Target vs current price
- +142.9%
- Analysts with a rating
- 7
- Share rating Buy or Strong Buy
- 71%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Sep 10, 2026 | +600.0% | +1.8% | -1.2% | — | — |
| Jul 27, 2026 | +120.0% | -1.1% | -12.6% | -19.1% | — |
| Mar 12, 2026 | -122.2% | -2.7% | -1.2% | -2.5% | -4.2% |
| Dec 15, 2025 | -75.0% | +16.1% | +7.4% | +5.1% | -14.6% |
| Sep 15, 2025 | -200.0% | +21.5% | -3.8% | -4.2% | -8.3% |
| Jul 23, 2025 | +35.0% | -1.3% | -18.2% | -2.9% | -16.2% |
| Mar 11, 2025 | +3200.0% | +10.0% | +14.0% | -11.2% | -28.3% |
| Dec 11, 2024 | +400.0% | +12.1% | +22.8% | +81.8% | +87.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Sep 10, 2026 | $0.05 | -$0.01 | +600.0% | $15.2M |
| Jul 27, 2026 | $0.01 | -$0.05 | +120.0% | $13.8M |
| Mar 12, 2026 | -$0.02 | $0.09 | -122.2% | $16.6M |
| Dec 15, 2025 | $0.02 | $0.08 | -75.0% | $15.0M |
| Sep 15, 2025 | -$0.03 | -$0.01 | -200.0% | $14.0M |
| Jul 23, 2025 | -$0.13 | -$0.20 | +35.0% | $12.4M |
| Mar 11, 2025 | $0.31 | -$0.01 | +3200.0% | $17.0M |
| Dec 11, 2024 | $0.05 | $0.01 | +400.0% | $13.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 49.4× | — | — | — |
| EV / EBITDA | 168.3× | — | — | Top 36% |
| EV / Sales | 1.24× | — | — | Top 14% |
| Free-cash-flow yield | -8.94% | — | — | Bottom 39% |
| Earnings yield | -1.60% | — | — | Top 34% |
P/E over the past five years
Range 22.7× – 304.1× since Oct 31, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -22.8%
- Earnings per share growth (TTM)
- -139.4%
- Change in P/E multiple
- -84.6%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.1%
- 200-day average slope (20 days)
- -2.4%
- Distance from 50-day average
- -3.8%
- Distance from 200-day average
- -17.0%
- RSI (14)
- 46.3
- Relative volume
- 0.24×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 45.2%
- Volatility vs own 5-year history
- 30th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.27
- Correlation with S&P 500
- 0.07
- Current drawdown from 1-year high
- -36.7%
- Maximum drawdown, 3 years
- -59.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 16, 2021 | Dec 20, 2022 | -72.7% | 446 days | Not yet recovered |
| Nov 20, 2020 | Jan 11, 2021 | -20.1% | 33 days | 43 days (Mar 15, 2021) |
| Oct 8, 2020 | Nov 2, 2020 | -11.3% | 17 days | 6 days (Nov 10, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $68.6M
- EPS, diluted (TTM)
- -$0.08
- Revenue (TTM)
- $60.7M
- 52-week range
- $4.59 – $8.31
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Revenue | $49.1M | $53.9M | $50.2M | $56.9M | $59.4M |
| Gross profit | $25.5M | $24.3M | $20.8M | $28.6M | $28.5M |
| Operating income | $607,000 | -$4.4M | -$6.9M | $4.8M | -$1.1M |
| Net income | $548,000 | -$5.3M | -$7.3M | $4.7M | -$1.2M |
| EPS (diluted) | $0.04 | -$0.39 | -$0.54 | $0.33 | -$0.08 |
| Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $17.0M | $12.4M | $14.0M | $15.0M | $16.6M | $13.8M | $15.2M |
| Net income | $728,000 | $4.5M | -$1.8M | -$466,000 | $299,000 | -$279,000 | -$729,000 | -$426,000 |
| EPS (diluted) | $0.05 | $0.31 | -$0.13 | -$0.03 | $0.02 | -$0.02 | -$0.05 | -$0.03 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Operating cash flow | $6.5M | $4.0M | -$6.1M | $7.4M | -$4.5M |
| Capital expenditure | -$2.4M | -$2.9M | -$836,000 | -$389,000 | -$564,000 |
| Free cash flow | $4.1M | $1.1M | -$7.0M | $7.0M | -$5.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $207,000 | $11,000 | -$381,000 | $320,000 | $234,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $4.4M
- Total assets
- $33.3M
- Total liabilities
- $28.8M
- Total debt
- $11.0M
- Net debt
- $6.6M
- Shareholders’ equity
- $3.9M
As of Jul 31, 2026 (filed Sep 11, 2026).
Short interest
- Shares sold short
- 68,463
- Days to cover
- 5.52
- Change vs previous report
- -7.8%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Aug 12, 2015
- 1-for-12